The United States and the United Kingdom have successfully negotiated a landmark deal eliminating tariffs on pharmaceuticals, ensuring better access to medicines for UK patients while boosting investment in the life sciences sector. As part of the agreement, the UK has committed to increasing its spending on pharmaceuticals, agreeing to pay up to 25% more for new drugs in exchange for avoiding tariffs. This significant deal follows months of negotiations and pressures from the Trump administration regarding NHS drug pricing. UK pharmaceutical exports to the US will now be duty-free under this new trade arrangement.